Identification of optimum spectacle prescriptions for patients with Down syndrome
唐氏综合症患者最佳眼镜处方的确定
基本信息
- 批准号:10661743
- 负责人:
- 金额:$ 39.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-01 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:Activities of Daily LivingAddressAdultAdvocateAffectAgeAmblyopiaBackChildChildhoodClinicalCognitiveCompensationCorneaCorneal TopographyCrossover DesignDevelopmentDisabled PersonsDown SyndromeEarly InterventionEducationEnrollmentEvaluationExposure toEyeEyeglassesFosteringFundingGoalsHealthHybridsHyperopiaImageImpaired cognitionIndividualLeadMeasurementMeasuresMethodologyMethodsMissionNational Eye InstituteOpticsOutcomePatientsPersonsPopulationPrintingProcessProtocols documentationRandomizedReadingRefractive ErrorsResearchTechniquesTestingUnited StatesUpdateVisionVisitVisualVisual AcuityWorkclinical examinationcohortexperienceexpirationfollow-upimprovedinnovationmonocularnovel therapeutic interventionpatient populationpreventprimary outcomepublic health relevancerate of changeretinal imagingsimulationstemtooltreatment armtreatment trialvisual performance
项目摘要
Project Summary/Abstract: It is known that individuals with Down syndrome (DS) have reduced visual acuity
which may result from high levels of refractive error (sphere and cylinder) and elevated levels of higher-order
aberrations that are present from childhood. Targeting optical aberrations through spectacle correction with
refractions determined objectively from measures of wavefront aberrations is part of our long-term goal to
provide new treatment strategies to improve vision in this group. The central hypothesis is that measures of
visual and retinal image quality (metrics) can be used to identify sphere and cylinder corrections that optimize
vision, resulting in multi-line acuity gains over traditional corrections. Our previous evaluation of these
corrections in adults with DS found improvement in acuity, but not the multi-line levels predicted. We propose
that this mismatch in acuity gains is attributed to decades of exposure to poorly corrected optical deficits that
has resulted in a reduction in visual acuity potential (i.e. refractive amblyopia). Further, the method is inherently
monocular, and does not prescribe refractions reflective of the two-eyed visual experience of the patient, as
would occur in a clinical exam. The short-term goal of this work is to address these proposed barriers to multi-
line acuity improvements with metric-optimized refractions through a randomized treatment trial conducted in
children with DS who are within the optimal age for treatment of amblyopia. This trial will compare acuity
outcomes for three refractive methods: 1) metric-optimized refractions, 2) clinical refractions, and 3) a hybrid
method that allows for clinical refinement of the metric-optimized refraction. In addition, we seek to improve the
objective refraction process by removing dilation prior to the wavefront imaging necessary to compute the
metric values, as well as determining the rate of change in refraction during extended follow-up to guide patient
recall times (i.e. follow-up intervals) for updated refraction. This work will be accomplished through three
specific aims: Aim 1) Compare refractions and resultant visual acuity obtained from wavefront measures pre-
and post-dilation. Aim 2) Compare visual acuity outcomes of metric-optimized, clinical, and clinically-refined
metric-optimized refractions in a treatment trial of children with DS. Aim 3) Determine rate of change in
refraction as a function of age and refractive error type annually over four years in children and adults with DS.
Metric-optimized refraction is innovative in that it compensates for the absence of subjective input in the
refraction process for the DS population and allows the clinician to consider corrections targeting overall image
quality. This proposed research is significant in that it proposes to use spectacles in an optimized manner to
remove visual barriers. Treatment of refractive amblyopia with multi-line acuity gains would lead to lifelong
benefits, including access to traditional print size, facilitate educational efforts, and facilitate activities of daily
living, all of which may promote greater independence. This work is similarly applicable to other patient
populations who cannot fully participate in subjective refractions (young children, cognitively impaired, etc.).
项目摘要/摘要:唐氏综合症(DS)患者的视力下降是众所周知的
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
A Randomized Trial of Objective Spectacle Prescriptions for Adults with Down Syndrome: Baseline Data and Methods.
- DOI:10.1097/opx.0000000000001631
- 发表时间:2021-01-01
- 期刊:
- 影响因子:0
- 作者:Anderson HA;Benoit JS;Marsack JD;Manny RE;Ravikumar A;Fern KD;Trast KR
- 通讯作者:Trast KR
Ciliary muscle thickness in adults with Down syndrome.
- DOI:10.1111/opo.12974
- 发表时间:2022-07
- 期刊:
- 影响因子:2.9
- 作者:Anderson, Heather A.;Bailey, Melissa D.;Manny, Ruth E.;Kao, Chiu-Yen
- 通讯作者:Kao, Chiu-Yen
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Heather Anne Anderson其他文献
Heather Anne Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Heather Anne Anderson', 18)}}的其他基金
Identification of optimum spectacle prescriptions for patients with Down syndrome
唐氏综合症患者最佳眼镜处方的确定
- 批准号:
10436324 - 财政年份:2014
- 资助金额:
$ 39.24万 - 项目类别:
Identification of optimum spectacle prescriptions for patients with Down syndrome
唐氏综合症患者最佳眼镜处方的确定
- 批准号:
10209686 - 财政年份:2014
- 资助金额:
$ 39.24万 - 项目类别:
Identification of optimum spectacle prescriptions for patients with Down syndrome
唐氏综合症患者最佳眼镜处方的确定
- 批准号:
8748949 - 财政年份:2014
- 资助金额:
$ 39.24万 - 项目类别:
Short Term Training: Students in Health Professional Schools
短期培训:卫生专业学校的学生
- 批准号:
10391486 - 财政年份:1998
- 资助金额:
$ 39.24万 - 项目类别:
Short Term Training: Students in Health Professional Schools
短期培训:卫生专业学校的学生
- 批准号:
10601021 - 财政年份:1998
- 资助金额:
$ 39.24万 - 项目类别:
Short Term Training: Students in Health Professional Schools
短期培训:卫生专业学校的学生
- 批准号:
9704789 - 财政年份:1998
- 资助金额:
$ 39.24万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 39.24万 - 项目类别:
Research Grant














{{item.name}}会员




